Author of

• 12021

  +

  MO12 - Prognostic and Predictive Biomarkers III (ID 96)

  • Event: WCLC 2013
  • Type: Mini Oral Abstract Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:B. Han, M. Edelman
  • Coordinates: 10/29/2013, 10:30 - 12:00, Parkside Ballroom B, Level 1

  • 12029

    +

    MO12.08 - Hepatocyte growth factor (HGF) serum levels predict for outcome in patients with Small Cell Lung Carcinoma (SCLC) (ID 2720)

    11:15 - 11:20  |  Author(s): X. Villanueva
    • Abstract
    • Presentation
    • Slides

    Background
    Small cell lung cancer (SCLC) accounts for approximately 15% of lung cancers. Treatment for SCLC has not changed in recent years and no targeted therapy has shown an increase in survival. We have previouly shown that Met phosphorylation is an adverse prognostic factor in this disease, suggesting a potential interest of Met targeted therapies in the treatment of SCLC patients. The aims of our study were to evaluate serum levels of the Met ligand, the hepatocyte growth factor (HGF) in patients with SCLC and to assess the correlations with other clinical variables and survival.

    Methods
    This is a prospective study conducted between 2009 and 2012. Serum samples were obtained from patients with SCLC at diagnosis, at first evaluation of response to standard chemotherapy by computerized tomography (CT) and at progression/relapse (first event). HGF levels were assessed by ELISA using the Quantikine commercial kit (R&D Systems, Minneapolis, MN). We evaluated the association between HGF levels and clinical-pathological variables by the Mann-Whitney tests and with survival in univariate (log-rank test) and multivariate analysis (Cox regression), assuming a statistical significance of p <0.05.

    Results
    Fifty-nine patients were included in this study. Median follow-up was 11 months. Patients’ characteristics are summarized in Table 1. The median serum HGF (range) at diagnosis, response and progression were 1750 pg/ml (651-9853), 1573 pg/ml (593-8518) and 1461 pg/ml (553-12956), respectively. In 72.5% of cases HGF levels decreased after 3 cycles of chemotherapy (platinum+etoposide). From the response time point to progression, 50% patients showed an increase in the HGF levels. The median overall survival (OS) for the entire population was 11,8 months(95% CI 6.4-14.8). The median OS for patients with high basal HGF (above 1750pg/ml) was 7,9 months vs 16,7 months for patients with basal HGF below the median. Patients whose HGF levels increased at progression presented a decreased survival (9,23 months) vs. those with a decrease (15,11 months) (p=0.032). In the multivariate analysis, PS> 1 (HR: 5.57, 95% CI 2.63-11.77 p < 0.001), stage IV (HR: 4.28, 95% CI 1.76-10.44 p = 0.001) and elevated HGF basal levels were independently associated with worse OS (HR: 3.32, 95% CI 1.57-7.03, p =0.002).

    Patients' characteristics

    		N (%)
    Median age		65.6 (46-86)
    Gender	Male	48 (81.4)
    	Female	11 (18.6)
    Smoking status	Current	40 (67.8)
    	Former	18 (30.5)
    	Never	1 (1.7)
    Performance status	0-1	44 (74.6)
    	2-3	15 (25.4)
    Stage	I-III	16 (27.1)
    	IV	43 (72.9)

    Conclusion
    HGF serum levels at diagnosis and changes during treatment are predictors of survival in patients with SCLC treated with standard first-line chemotherapy.

    Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.